MétaCan
Menu
Back to cohort
Record W3134546140 · doi:10.3899/jrheum.201351

Antineutrophil Cytoplasmic Antibody-associated Vasculitis Management 2020: Where Are We Now?

2021· letter· en· W3134546140 on OpenAlexvenueaboutno aff
David Jayne

Bibliographic record

VenueThe Journal of Rheumatology · 2021
Typeletter
Languageen
FieldMedicine
TopicVasculitis and related conditions
Canadian institutionsnot available
Fundersnot available
KeywordsMedicineMicroscopic polyangiitisRituximabAnti-neutrophil cytoplasmic antibodyVasculitisGranulomatosis with polyangiitisRheumatologyIntensive care medicineProteinase 3Internal medicineEosinophilicImmunologyDiseasePathologyAntibody

Abstract

fetched live from OpenAlex

The management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) has come a long way from the first postmortem descriptions of the diseases in the 1930s and 1950s1. Pivotal phases have been the introduction of glucocorticoids (GC) and cyclophosphamide (CYC), the association with ANCA in the 1980s, and consensus classification and nomenclature systems from 1990 onwards2. These advances laid the foundations for larger-scale clinical investigations that have informed both the development of recommendations statements in the 2000s and the evaluation of newer therapies3. In parallel with these activities have been improvements in physician training and healthcare delivery, which have shortened diagnostic delay, and improved mortality and endstage renal disease risks4. Statements to guide AAV management have now been produced at national and international levels, and an update of the Canadian Vasculitis Society (CanVasc) 2015 statement is published in this edition of The Journal of Rheumatology 5. This is an extensive piece of work with 39 recommendation statements, 15 of them new for this update covering diagnosis, drug therapies, eosinophilic granulomatosis with polyangiitis (EGPA), children, monitoring, and prophylaxis. So what is new? Solid-phase assays for proteinase 3–ANCA and myeloperoxidase (MPO)-ANCA are the preferred initial serologic tests reflecting superior performance when compared to indirect immunofluorescence (cytoplasmic or perinuclear ANCA). There is more discussion on GC dosing as better data have emerged and momentum builds to limit doses. The place of rituximab (RTX) has been extended to relapse prevention; plasma exchange use is more restricted; and mycophenolate mofetil (MMF) is an alternative induction option. The use of biomarkers to guide drug dosing during remission maintenance, … Address correspondence to Dr. D. Jayne, Box 157, Department of Medicine, Addenbrookes Hospital, Cambridge CB22QQ, UK. Email: Dj106{at}cam.ac.uk.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.005
metaresearch head score (Gemma)0.014
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: Not applicable
GenreCandidate signal: Commentary · Consensus signal: Commentary
Teacher disagreement score0.042
Threshold uncertainty score0.140

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0050.014
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0010.001
Science and technology studies0.0020.001
Scholarly communication0.0060.007
Open science0.0020.002
Research integrity0.0070.009
Insufficient payload (model declined to judge)0.0420.019

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.011
GPT teacher head0.248
Teacher spread0.238 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreCommentary

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations2
Published2021
Admission routes2
Has abstractyes

Explore more

Same venueThe Journal of RheumatologySame topicVasculitis and related conditionsFrench-language works237,207